SG Americas Securities LLC Grows Stock Holdings in Immunome, Inc. $IMNM

SG Americas Securities LLC increased its position in Immunome, Inc. (NASDAQ:IMNM) by 1,749.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 162,168 shares of the company’s stock after buying an additional 153,399 shares during the quarter. SG Americas Securities LLC’s holdings in Immunome were worth $3,483,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Immunome by 44.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock valued at $316,000 after acquiring an additional 14,398 shares in the last quarter. Creative Planning purchased a new stake in shares of Immunome during the second quarter worth about $167,000. Swiss National Bank raised its stake in Immunome by 3.8% during the 2nd quarter. Swiss National Bank now owns 132,800 shares of the company’s stock valued at $1,235,000 after purchasing an additional 4,800 shares during the period. Rhumbline Advisers raised its stake in Immunome by 22.0% during the 2nd quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock valued at $1,008,000 after purchasing an additional 19,526 shares during the period. Finally, Lido Advisors LLC lifted its holdings in Immunome by 11.5% in the 2nd quarter. Lido Advisors LLC now owns 59,085 shares of the company’s stock worth $549,000 after purchasing an additional 6,085 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Insider Activity at Immunome

In related news, Director Philip Wagenheim sold 36,800 shares of the firm’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $20.47, for a total value of $753,296.00. Following the completion of the transaction, the director directly owned 369,347 shares of the company’s stock, valued at approximately $7,560,533.09. This trade represents a 9.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.69% of the company’s stock.

Immunome Trading Down 2.7%

NASDAQ:IMNM opened at $21.84 on Friday. The business’s 50-day moving average is $22.42 and its 200 day moving average is $19.13. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $27.65. The company has a market capitalization of $2.47 billion, a P/E ratio of -9.02 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.10). On average, research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on IMNM shares. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Stephens reduced their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a report on Thursday, January 22nd. Lake Street Capital upped their target price on shares of Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Finally, Guggenheim raised their target price on shares of Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $33.45.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.